Under Development

Dry eye drops:

Some patients with simple asthenopia or VDT dry eye disease have low levels of AJ in their tears, which leads to the damage of the protective barrier on the ocular surface showing serious dry eye symptoms and it is difficult to repair. At present, only Symptom-relieving medicines can be provided for dry eye patients at home and abroad. The most commonly used medicines are anti-inflammatory eye drops, and the rest are basically tear film repair medicine or artificial tears. The effect of rhAJ as artificial tear is good. It has the anti-inflammatory effect similar to cyclosporine and has unique effect of inhibiting keratosis and squamous metaplasia of the conjunctiva of the eye corner.

 

 Animal experiment and pathological examination showed that rhAJ and natural AJ protein as eye drops could inhibit the apoptosis of keratin and conjunctiva epithelial cells, and repair the damage of keratin and conjunctiva epithelial cell layer. RhAJ can repair the tear film mucin layer damage by directly binding with mucin, which explains the significant effect of rhAJ on dry eye disease indicated by fluorescence staining.

 

 From the perspective of the mechanism of action, rhAJ is the only molecule found in the world that can simultaneously repair and protect the tear film mucin layer and keratoconjunctiva epithelial cells.

 

 It is expected for our company to apply for the eye drops clinical approval of Chinese FDA in the next 24 months, and then apply for the clinical approval of the United States FDA.